Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GLAXO's NEW PRESIDENT IS FORMER SQUIBB EXEC ERNEST MARIO, PhD

Executive Summary

GLAXO's NEW PRESIDENT IS FORMER SQUIBB EXEC ERNEST MARIO, PhD, who will also serve in the newly created position of chief operating officer of the British pharmaceutical firm's U.S. subsidiary. "Dr. Mario takes over duties formerly exercised" by former president Joseph Ruvane, Glaxo reported in a Sept. 2 release. Ruvane, however, retains the top spot at the U.S. subsidiary and will continue to hold the title of chief executive officer. Mario, 48, joined Squibb as a VP-manufacturing, U.S. Pharmaceutical division in 1977 and eventually became group VP of the Squibb Corporation, a member of its board and president and chief exec of the Squibb Medical Products Group. "He was largely credited with engineering the return to profitability of Squibb's Seattle-based medical electronics business," the release states. Mario's experience with pharmaceuticals, however, will be more important in his new job at Glaxo; the company does not have a medical products business in the U.S. Prior to his stint with Squibb, Mario served as VP of manufacturing operations for SmithKline. A former NIH research fellow, Mario received his bachelor's degree in pharmacy from Rutgers and his master's and doctorate degrees from the University of Rhode Island. In July, Squibb announced its intention to spinoff three of its medical products businesses -- Advanced Technology Labs, Spacelabs and its overseas ultrasound distribution operations -- into a new company, Westmark International, headed by former Squibb President Dennis Fill. Last week, Squibb consolidated the remaining three medical products units with its pharmaceutical operations under new exec VP Jan Leschly. Ruvane, 61, was recently elected to the board of Glaxo's British parent, Glaxo Holdings Ltd., and given responsibility for Glaxo Argentina and Glaxo Latin America. For the fiscal year ended June 30, 1985, Glaxo reported sales of $356 mil. Sales have grown steadily in 1986, largely through the success of the company's antiulcer product, Zantac.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS010679

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel